RxDoctor Payments Data

Duane Whitlock, MD

Ophthalmology · Gettysburg, PANPI 1821098229

Payments from drug & device makers

$24,811in general payments, 2019–2025

Across 250 payments — averaging $99.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$20K
  • Sun Pharmaceutical Industries Inc.$825
  • AbbVie$745
  • Mallinckrodt Hospital Products Inc.$652
  • Alcon$623
  • Bausch & Lomb Americas Inc.$353
  • plus $2K from 18 others

What the payments were for

  • Speaking & faculty fees$261%
  • Food & beverage$4,54695%
  • Education$2185%
  • Gifts$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$24,811 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$370,347
Medicare patients
676
Services billed
1,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost139$88,724
RestasisCyclosporine34$50,854
XiidraLifitegrast23$27,668
Cyclosporine33$25,499
Travoprost67$15,789
TyrvayaVarenicline Tartrate14$13,664
CombiganBrimonidine Tartrate/Timolol23$13,017
CequaCyclosporine11$11,920
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol43$9,976
ProlensaBromfenac Sodium28$9,384
Prednisolone Acetate294$7,986
Latanoprost434$7,720
Timolol Maleate237$6,800
SimbrinzaBrinzolamide/Brimonidine Tart23$6,549
Alphagan PBrimonidine Tartrate13$6,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$745$158,970209 claims
Bausch & Lomb Americas Inc.Xiidra$353$27,66823 claims
Oyster Point Pharma, Inc.Tyrvaya$154$13,66414 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm$147$12,90241 claims
Sun Pharmaceutical Industries Inc.Cequa$825$11,92011 claims
AlconSimbrinza$623$6,54923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Gettysburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →